These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33076344)

  • 1. The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD.
    Östlund C; Hernandez-Ono A; Shin JY
    Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33076344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear envelope-localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis.
    Shin JY; Hernandez-Ono A; Fedotova T; Östlund C; Lee MJ; Gibeley SB; Liang CC; Dauer WT; Ginsberg HN; Worman HJ
    J Clin Invest; 2019 Aug; 129(11):4885-4900. PubMed ID: 31408437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Arab JP; Arrese M; Trauner M
    Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid receptors and nonalcoholic fatty liver disease.
    Yuan L; Bambha K
    World J Hepatol; 2015 Dec; 7(28):2811-8. PubMed ID: 26668692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
    Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
    FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic regulation of hepatic lipid metabolism by torsinA and its activators.
    Hernandez-Ono A; Zhao YP; Murray JW; Östlund C; Lee MJ; Shi A; Dauer WT; Worman HJ; Ginsberg HN; Shin JY
    JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38194265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.
    Nagaya T; Tanaka N; Kimura T; Kitabatake H; Fujimori N; Komatsu M; Horiuchi A; Yamaura T; Umemura T; Sano K; Gonzalez FJ; Aoyama T; Tanaka E
    BBA Clin; 2015 Jun; 3():168-74. PubMed ID: 26674248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis.
    Anderson N; Borlak J
    Pharmacol Rev; 2008 Sep; 60(3):311-57. PubMed ID: 18922966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis.
    Zhu L; Baker SS; Liu W; Tao MH; Patel R; Nowak NJ; Baker RD
    Metabolism; 2011 Jul; 60(7):1001-11. PubMed ID: 21075404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis.
    Parafati M; Kirby RJ; Khorasanizadeh S; Rastinejad F; Malany S
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30254132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: from lipid profile to treatment.
    Miura K; Ohnishi H
    Clin J Gastroenterol; 2012 Oct; 5(5):313-21. PubMed ID: 26181068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
    Mato JM; Alonso C; Noureddin M; Lu SC
    World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
    Musso G; Anty R; Petta S
    Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSD17B13: A Potential Therapeutic Target for NAFLD.
    Zhang HB; Su W; Xu H; Zhang XY; Guan YF
    Front Mol Biosci; 2021; 8():824776. PubMed ID: 35071330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.